Home

Detektor Tom Audreath pobyt cd38 marker multiple myeloma vzdělávání Kreslit Mírný

Inhibition of DEPDC1A, a Bad Prognostic Marker in Multiple Myeloma, Delays Growth and Induces Mature Plasma Cell Markers in Malignant Plasma Cells | PLOS ONE
Inhibition of DEPDC1A, a Bad Prognostic Marker in Multiple Myeloma, Delays Growth and Induces Mature Plasma Cell Markers in Malignant Plasma Cells | PLOS ONE

Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab | Leukemia
Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab | Leukemia

International Clinical Cytometry Society
International Clinical Cytometry Society

CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance | Semantic Scholar
CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance | Semantic Scholar

Tissue biodistribution and tumor targeting of near-infrared labelled anti- CD38 antibody-drug conjugate in preclinical multiple myeloma | Oncotarget
Tissue biodistribution and tumor targeting of near-infrared labelled anti- CD38 antibody-drug conjugate in preclinical multiple myeloma | Oncotarget

Mechanism of Action of a New Anti-CD38 Antibody: Enhancing Myeloma Immunotherapy | Semantic Scholar
Mechanism of Action of a New Anti-CD38 Antibody: Enhancing Myeloma Immunotherapy | Semantic Scholar

Immunophenotyping in Multiple Myeloma and Others Monoclonal Gammopathies | IntechOpen
Immunophenotyping in Multiple Myeloma and Others Monoclonal Gammopathies | IntechOpen

Regulation of CD38 on Multiple Myeloma and NK Cells by Monoclonal Antibodies
Regulation of CD38 on Multiple Myeloma and NK Cells by Monoclonal Antibodies

Immunophenotyping in Multiple Myeloma and Others Monoclonal Gammopathies | IntechOpen
Immunophenotyping in Multiple Myeloma and Others Monoclonal Gammopathies | IntechOpen

PDF] Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma | Semantic Scholar
PDF] Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma | Semantic Scholar

Double CD38−/CD138− negative multiple myeloma - ScienceDirect
Double CD38−/CD138− negative multiple myeloma - ScienceDirect

Frontiers | Daratumumab for the Treatment of Multiple Myeloma
Frontiers | Daratumumab for the Treatment of Multiple Myeloma

Annotating CD38 Expression in Multiple Myeloma with [18F]F–Nb1053 | Molecular Pharmaceutics
Annotating CD38 Expression in Multiple Myeloma with [18F]F–Nb1053 | Molecular Pharmaceutics

Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formatio
Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formatio

ePosters - Inecalcitol Stimulates CD38 Expression in Multiple Myeloma and Acute Myeloid Leukemia Cell Lines
ePosters - Inecalcitol Stimulates CD38 Expression in Multiple Myeloma and Acute Myeloid Leukemia Cell Lines

Cureus | Secondary Plasma Cell Leukemia in a Recurrent Multiple Myeloma: Rare Case Scenario | Article
Cureus | Secondary Plasma Cell Leukemia in a Recurrent Multiple Myeloma: Rare Case Scenario | Article

CD38, A Target for Immunotherapeutic Approaches in Cancer
CD38, A Target for Immunotherapeutic Approaches in Cancer

Comparison of CD38-Targeted α- Versus β-Radionuclide Therapy of Disseminated Multiple Myeloma in an Animal Model | Journal of Nuclear Medicine
Comparison of CD38-Targeted α- Versus β-Radionuclide Therapy of Disseminated Multiple Myeloma in an Animal Model | Journal of Nuclear Medicine

CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma - ScienceDirect
CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma - ScienceDirect

Cells | Free Full-Text | Novel Insights in Anti-CD38 Therapy Based on CD38-Receptor Expression and Function: The Multiple Myeloma Model
Cells | Free Full-Text | Novel Insights in Anti-CD38 Therapy Based on CD38-Receptor Expression and Function: The Multiple Myeloma Model

Pre-treatment CD38-positive regulatory T cells affect the durable response to daratumumab in relapsed/refractory multiple myeloma patients | Haematologica
Pre-treatment CD38-positive regulatory T cells affect the durable response to daratumumab in relapsed/refractory multiple myeloma patients | Haematologica

Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide
Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide

CD38-targeted Immuno-PET of Multiple Myeloma: From Xenograft Models to First-in-Human Imaging | Radiology
CD38-targeted Immuno-PET of Multiple Myeloma: From Xenograft Models to First-in-Human Imaging | Radiology

Expression of CD38 in normal and malignant plasma cells.... | Download Scientific Diagram
Expression of CD38 in normal and malignant plasma cells.... | Download Scientific Diagram

Detect CD38 expression during anti-CD38 therapy – Caltag Medsystems
Detect CD38 expression during anti-CD38 therapy – Caltag Medsystems